The Daily Biotech Pulse: Cesca, Acer Therapeutics Rally On Earnings, Aridis Makes Its Nasdaq Debut

Here's a roundup of top developments in the biotech space over the last 24 hours.

Scaling the Peaks

(Stocks hitting 52-week highs on Aug. 13)

• Iradimed Corp IRMD
• SurModics, Inc. SRDX

Down In The Dumps

(Stocks hitting 52-week lows on Aug. 13)

• Acasti Pharma ACST
• Achaogen Inc AKAO
• Agile Therapeutics Inc AGRX
• Arsanis Inc ASNS(reported a wider-than-expected loss for its Q2)
• aTyr Pharma Inc LIFE
• Aytu BioScience AYTU (1-for-20 reverse stock split became effective)
• Cleveland BioLabs, Inc. CBLI
• DelMar Pharmaceuticals Inc DMPI
• IntelliPharmaCeutics Intl Inc (USA) IPCI
• Osiris Therapeutics, Inc. OSIR
• Portola Pharmaceuticals PTLA
• Puma Biotechnology Inc PBYI
• Surface Oncology Inc SURF
• Synlogic Inc SYBX
• Titan Medical Inc. TMDI(reacted to the announcement of Q2 results)
• VBI Vaccines Inc VBIV

Stocks In Focus

Stocks Reacting To Earnings

VolitionRX Ltd VNRX reported a loss of 15 cents per share for the second quarter, wider than the loss of 13 cents per share last year. Analysts, on average, estimated a loss of 14 cents per share. Cash and cash equivalents as of June 30, 2018 totaled $11.9 million.

The stock rose 3.66 percent to $1.98 in after-hours session.

Cesca Therapeutics Inc KOOL reported second-quarter net revenues of $2 million compared to $3.5 million last year, with the decline attributed to lower AXP sales due to a change in a distributor in China, lower BioArchive device sales and the termination of a royalty payment agreement last year.

The loss per share widened from 12 cents in Q217 to $1.73 in Q218. The stock jumped 11.76 percent to $11.76 percent in after-hours trading.

See Also: The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs

ENDRA Life Sciences Inc NDRA reported a loss of 47 cents per share for its second quarter compared to a loss of 59 cents per share in the year-ago quarter.

The stock gained 4.01 percent to $2.36 in after-hours trading.

Acer Therapeutics Inc ACER said its second-quarter loss narrowed from $1.29 in Q217 to 64 cents per share in Q218. The consensus estimate had called for a loss of 55 cents per share.

The stock jumped 9.03 percent to $31.62 in after-hours trading.

On The Radar

Earnings

• Athenex Inc ATNX Q2 EPS $(0.58) Misses $(0.48) Estimate, Sales $11.6M Miss $14.42M Estimate
• Array Biopharma Inc ARRY Q4 EPS $(0.25) Misses $(0.24) Estimate, Sales $35.4M Miss $38.73M Estimate
• Bioanalytical Systems, Inc. BASI(before the market open)
• Cancer Genetics Inc CGIX Q2 EPS $(0.13) Beats $(0.16) Estimate, Sales $7.036M Miss $8.3M Estimate
• Eyenovia Inc EYEN Q2 EPS $(0.33) Beats $(0.42) Est.
• Urogen Pharma Ltd URGN Q2 EPS $(1.14) Misses $(0.89) Estimate, Sales $364K
• Neuronetics Inc STIM Q2 EPS $(30.60) Misses $(0.84) Estimate, Sales $13.252M Beat $12.32M Estimate
• Onconova Therapeutics Inc ONTX Q2 EPS $(0.07) Beats $(0.08) Estimate, Sales $485K Beat $220K Estimate
• OptiNose Inc OPTN Q2 EPS $(0.64) Beats $(0.77) Estimate, Sales $1.274M Beat $1.25M Estimate
• Aerpio Pharmaceuticals Inc ARPO Q2 EPS $(0.22) Beats $(0.23) Est., Sales $1.33M May Not Compare To $670K Est.
• aTyr Pharma Inc LIFE (after the market close)
• Cytori Therapeutics Inc CYTX (after the market close)
• Biocept Inc BIOC (after the market close)
• Reshape Lifesciences Inc RSLS (after the market close)
• RXi Pharmaceuticals Corp RXII (after the market close)
• Precision Therapeutics Inc AIPT (after the market close)

IPO

Aridis Pharmaceuticals priced its offering of 2 million shares at $13 per share, at the low end of the estimated price range of $13-$15. The shares will begin trading on the Nasdaq under the ticker symbol ARDS.